https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma.
marginal zoneiphinnatepharmanodal
https://www.pharmaceutical-technology.com/data-insights/zolacabtagene-autoleucel-bristol-myers-squibb-marginal-zone-b-cell-lymphoma-likelihood-of-approval/
Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.
bristol myers squibbmarginal zone
https://www.mdanderson.org/newsroom/single-agent-umbralisib-effective-for-relapsed-slow-growing-lymphoma.h00-159301467.html
Apr 1, 2019 - A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed...
marginal zone lymphomaanderson cancer centereffectivemd
https://www.pharmaceutical-technology.com/data-insights/likelihood-of-approval-nodal-marginal-zone-b-cell-lymphoma/
Nodal Marginal Zone B-Cell Lymphoma disease is an indication for drug development with over 30 pipeline drugs currently active according to GlobalData.
b cell lymphomamarginal zonenodaldrugslikelihood
https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/
IPH-6501 is under clinical development by Innate Pharma and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.
marginal zoneiphinnatepharmasplenic
https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-marginal-zone-b-cell-lymphoma-likelihood-of-approval/
Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for Marginal Zone B-cell Lymphoma.
swedish orphan biovitrumloncastuximab tesirinemarginal zone
https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-marginal-zone-b-cell-lymphoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-212198&utm_campaign=recommended-articles-pi
Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma.
b cell lymphomaregeneron pharmaceuticalsmarginal zoneodronextamab
https://www.pharmaceutical-technology.com/data-insights/zeripatamig-light-chain-bioscience-marginal-zone-b-cell-lymphoma-likelihood-of-approval/
Zeripatamig is under clinical development by Light Chain Bioscience and currently in Phase I for Marginal Zone B-cell Lymphoma.
light chainmarginal zoneb cellbioscience
https://www.pharmaceutical-technology.com/data-insights/jnj-8543-johnson-johnson-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/
JNJ-8543 is under clinical development by Johnson & Johnson and currently in Phase I for Splenic Marginal Zone B-Cell Lymphoma.
marginal zonejnjjohnsonsplenicb
https://www.pharmaceutical-technology.com/data-insights/aurixim-biointegrator-marginal-zone-b-cell-lymphoma-likelihood-of-approval/
Aurixim is under clinical development by BioIntegrator and currently in Phase I for Marginal Zone B-cell Lymphoma.
b cell lymphomamarginal zonelikelihood